New Two-Drug combo enters human testing for Tough-to-Treat cancers
NCT ID NCT05789069
Summary
This is an early-stage study to find a safe dose of a new drug called HFB200603, given alone or with an existing immunotherapy (tislelizumab), for people with advanced cancers that have stopped responding to standard treatments. The trial will enroll about 83 adults with specific advanced cancers like kidney, lung, melanoma, stomach, or colorectal cancer. Researchers will first test increasing doses to check safety, then give the chosen doses to more patients to see how their cancers respond.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Centro Ricerche Cliniche di Verona s.r.l.
Verona, 37134, Italy
-
Clinica Universidad de Navarra - Madrid
Madrid, 28027, Spain
-
Clinica Universidad de Navarra - Pamplona
Pamplona, 31008, Spain
-
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19111, United States
-
Hospital Clinico Universitario de Valencia
Valencia, 46010, Spain
-
Istituto Nazionale Tumori IRCCS Fondazione G. Pascale
Naples, 80131, Italy
-
New Experimental Therapeutics of Virginia - NEXT Oncology
Fairfax, Virginia, 22031, United States
-
South Texas Accelerated Research Therapeutics (START) Madrid - CIOCC
Madrid, 28050, Spain
-
South Texas Accelerated Research Therapeutics (START) Madrid - Hospital Fundacion Jimenez Diaz
Madrid, 28040, Spain
-
UOC Fase I - Fondazione Policlinico Universitario A. Gemelli IRCCS - Universita Cattolica del Sacro Cuore
Rome, 00168, Italy
-
USC Norris Comprehensive Cancer Center
Los Angeles, California, 90033, United States
Conditions
Explore the condition pages connected to this study.